Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Calliditas Therapeutics AB publ stock
Learn how to easily invest in Calliditas Therapeutics AB publ stock.
Calliditas Therapeutics AB (publ) is a biotechnology business based in the US. Calliditas Therapeutics AB publ shares (CALT) are listed on the NASDAQ and all prices are listed in US Dollars. Calliditas Therapeutics AB publ employs 65 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Calliditas Therapeutics AB publ
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CALT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Calliditas Therapeutics AB publ stock price (NASDAQ: CALT)Use our graph to track the performance of CALT stocks over time.
Calliditas Therapeutics AB publ shares at a glance
|Latest market close||$23.17|
|52-week range||$14.22 - $33.19|
|50-day moving average||$19.92|
|200-day moving average||$25.38|
|Wall St. target price||$63.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Calliditas Therapeutics AB publ shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Calliditas Therapeutics AB publ stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Calliditas Therapeutics AB publ price performance over time
|1 week (2022-01-07)||-0.26%|
|1 month (2021-12-16)||1.05%|
|3 months (2021-10-15)||4.46%|
|6 months (2021-07-16)||-21.48%|
|1 year (2021-01-15)||-23.02%|
|2 years (2020-01-12)||N/A|
|3 years (2019-01-12)||N/A|
|5 years (2017-01-12)||N/A|
Calliditas Therapeutics AB publ financials
|Gross profit TTM||$874,000|
|Return on assets TTM||-16.85%|
|Return on equity TTM||-34.26%|
|Market capitalisation||$609.8 million|
TTM: trailing 12 months
Calliditas Therapeutics AB publ share dividends
We're not expecting Calliditas Therapeutics AB publ to pay a dividend over the next 12 months.
Calliditas Therapeutics AB publ share price volatility
Over the last 12 months, Calliditas Therapeutics AB publ's shares have ranged in value from as little as $14.22 up to $33.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calliditas Therapeutics AB publ's is 1.4517. This would suggest that Calliditas Therapeutics AB publ's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Calliditas Therapeutics AB publ overview
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden. .
Calliditas Therapeutics AB publ in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda
Frequently asked questionsWhat percentage of Calliditas Therapeutics AB publ is owned by institutions?
Currently 3.691% of Calliditas Therapeutics AB publ shares are held by institutions. How many people work for Calliditas Therapeutics AB publ?
Latest data suggests 65 work at Calliditas Therapeutics AB publ. When does the fiscal year end for Calliditas Therapeutics AB publ?
Calliditas Therapeutics AB publ's fiscal year ends in December. Where is Calliditas Therapeutics AB publ based?
Calliditas Therapeutics AB publ's address is: Kungsbron 1, C8, Stockholm, Sweden, 111 22 What is Calliditas Therapeutics AB publ's ISIN number?
Calliditas Therapeutics AB publ's international securities identification number is: US13124Q1067
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert